| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:2299-2306.)
© 2004 American Heart Association, Inc.
Arrhythmia/Electrophysiology |
From the Department of Pharmacology and Toxicology, Dresden University of Technology (E.W., T.C., J.F.H., D.D., U.R.), and the Cardiovascular Center (M.K.), Dresden, Germany; and the Department of Pharmacology and Pharmacotherapy, Medical University of Szeged, Szeged, Hungary (O.H., A.V.).
Correspondence to Dr Erich Wettwer, Fetscherstraße 74, 01307 Dresden, Germany. E-mail wettwer{at}rcs.urz.tu-dresden.de
Received November 4, 2003; de novo received April 5, 2004; revision received May 17, 2004; accepted May 21, 2004.
Background The ultrarapid outward current IKur is a major repolarizing current in human atrium and a potential target for treating atrial arrhythmias. The effects of selective block of IKur by low concentrations of 4-aminopyridine or the biphenyl derivative AVE 0118 were investigated on right atrial action potentials (APs) in trabeculae from patients in sinus rhythm (SR) or chronic atrial fibrillation (AF).
Methods and Results AP duration at 90% repolarization (APD90) was shorter in AF than in SR (300±16 ms, n=6, versus 414±10 ms, n=15), whereas APD20 was longer (35±9 ms in AF versus 5±2 ms in SR, P<0.05). 4-Aminopyridine (5 µmol/L) elevated the plateau to more positive potentials from 21±3 to 6±3 mV in SR and 0±3 to +12±3 mV in AF. 4-Aminopyridine reversibly shortened APD90 from 414±10 to 350±10 ms in SR but prolonged APD90 from 300±16 to 320±13 ms in AF. Similar results were obtained with AVE 0118 (6 µmol/L). Computer simulations of IKur block in human atrial APs predicted secondary increases in ICa,L and in the outward rectifiers IKr and IKs, with smaller changes in AF than SR. The indirect increase in ICa,L was supported by a positive inotropic effect of 4-aminopyridine without direct effects on ICa,L in atrial but not ventricular preparations. In accordance with the model predictions, block of IKr with E-4031 converted APD shortening effects of IKur block in SR into AP prolongation.
Conclusions Whether inhibition of IKur prolongs or shortens APD depends on the disease status of the atria and is determined by the level of electrical remodeling.
Key Words: ion channels potassium channel blockers contraction action potentials fibrillation
This article has been cited by other articles:
![]() |
I. Savelieva and J. Camm Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches Europace, June 1, 2008; 10(6): 647 - 665. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Yang, C. F. Browning, H. Hallaq, L. Yermalitskaya, J. Esker, M. R. Hall, A. J. Link, A.-J. L. Ham, M. J. McGrath, C. A. Mitchell, et al. Four and a half LIM protein 1: a partner for KCNA5 in human atrium Cardiovasc Res, June 1, 2008; 78(3): 449 - 457. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-R. Li, H.-B. Wang, G.-W. Qin, M.-W. Jin, Q. Tang, H.-Y. Sun, X.-L. Du, X.-L. Deng, X.-H. Zhang, J.-B. Chen, et al. Acacetin, a Natural Flavone, Selectively Inhibits Human Atrial Repolarization Potassium Currents and Prevents Atrial Fibrillation in Dogs Circulation, May 13, 2008; 117(19): 2449 - 2457. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Ehrlich, P. Biliczki, S. H. Hohnloser, and S. Nattel Atrial-Selective Approaches for the Treatment of Atrial Fibrillation J. Am. Coll. Cardiol., February 26, 2008; 51(8): 787 - 792. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tsujimae, S. Murakami, and Y. Kurachi In silico study on the effects of IKur block kinetics on prolongation of human action potential after atrial fibrillation-induced electrical remodeling Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H793 - H800. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Blaauw, U. Schotten, A. van Hunnik, H.R. Neuberger, and M.A. Allessie Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat Cardiovasc Res, July 1, 2007; 75(1): 89 - 98. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nattel, A. Maguy, S. Le Bouter, and Y.-H. Yeh Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation Physiol Rev, April 1, 2007; 87(2): 425 - 456. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Schotten, S. de Haan, S. Verheule, E. G.A. Harks, D. Frechen, E. Bodewig, M. Greiser, R. Ram, J. Maessen, M. Kelm, et al. Blockade of atrial-specific K+-currents increases atrial but not ventricular contractility by enhancing reverse mode Na+/Ca2+-exchange Cardiovasc Res, January 1, 2007; 73(1): 37 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Christ, E. Wettwer, and U. Ravens Letter by Christ et al Regarding Article, "Angiotensin II Potentiates the Slow Component of Delayed Rectifier K+ Current via the AT1 Receptor in Guinea Pig Atrial Myocytes" Circulation, October 31, 2006; 114(18): e565 - e565. [Full Text] [PDF] |
||||
![]() |
N. Decher, P. Kumar, T. Gonzalez, B. Pirard, and M. C. Sanguinetti Binding Site of a Novel Kv1.5 Blocker: A "Foot in the Door" against Atrial Fibrillation Mol. Pharmacol., October 1, 2006; 70(4): 1204 - 1211. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. de Haan, M. Greiser, E. Harks, Y. Blaauw, A. van Hunnik, S. Verheule, M. Allessie, and U. Schotten AVE0118, Blocker of the Transient Outward Current (Ito) and Ultrarapid Delayed Rectifier Current (IKur), Fully Restores Atrial Contractility After Cardioversion of Atrial Fibrillation in the Goat Circulation, September 19, 2006; 114(12): 1234 - 1242. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. El-Armouche, P. Boknik, T. Eschenhagen, L. Carrier, M. Knaut, U. Ravens, and D. Dobrev Molecular Determinants of Altered Ca2+ Handling in Human Chronic Atrial Fibrillation Circulation, August 15, 2006; 114(7): 670 - 680. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lagrutta, J. Wang, B. Fermini, and J. J. Salata Novel, Potent Inhibitors of Human Kv1.5 K+ Channels and Ultrarapidly Activating Delayed Rectifier Potassium Current J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1054 - 1063. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Christ and U. Ravens Do we need new antiarrhythmic compounds in the era of implantable cardiac devices and percutaneous ablation? Cardiovasc Res, December 1, 2005; 68(3): 341 - 343. [Full Text] [PDF] |
||||
![]() |
J. Camm Atrial fibrillation - an end to the epidemic? Circulation, August 23, 2005; 112(8): iii - iii. [Full Text] [PDF] |
||||
![]() |
S. V. Pandit, O. Berenfeld, J. M. B. Anumonwo, R. M. Zaritski, J. Kneller, S. Nattel, and J. Jalife Ionic Determinants of Functional Reentry in a 2-D Model of Human Atrial Cells During Simulated Chronic Atrial Fibrillation Biophys. J., June 1, 2005; 88(6): 3806 - 3821. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |